Compare Johnson & Johnson (JNJ) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Workday Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Workday Inc trades at $186.59 (market cap $45.26B). The key difference: Johnson & Johnson is far larger — about 13.7× Workday Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Workday Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Workday Inc for 38 Days on average.
| JNJ | WDAY | |
|---|---|---|
Market Cap | $618.09B | $45.26B |
Volume | 6,050,983 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $278.43 | $245.67 |
52-Week Low | $186.00 | $112.55 |
Typical Hold Time | 129 Days | 38 Days |
Enterprise Value | $646.37B | $45.63B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Workday (WDAY) trades at $187.81, up 1.93% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.75 exceeding the $2.61 forecast. Revenue growth is robust, projected to reach $10.2B in 2026, and the company maintains a high gross profit margin of 75.8%. Recent strategic moves include expansion into the UAE and AI product launches, though layoffs signal operational realignment.
The outlook for WDAY is positive, driven by AI integration and solid financials, but risks include competitive pressures and execution challenges. Analyst consensus is a Buy with a $202.92 price target, suggesting upside potential. Investors should weigh strong profitability against valuation multiples that remain elevated compared to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
